MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Natera Inc

Lezárt

SzektorEgészségügy

181.29 0.83

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

177.21

Maximum

182.12

Fő mutatók

By Trading Economics

Bevétel

-34M

-101M

Értékesítés

45M

547M

Profit margin

-18.467

Munkavállalók

4,424

EBITDA

-33M

-90M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+14.69% upside

Osztalékok

By Dow Jones

Következő eredményjelentés

2025. okt. 23.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

5.3B

24B

Előző nyitás

180.46

Előző zárás

181.29

Hangulat hírek alapján

By Acuity

48%

52%

157 / 371 Rangsor szerint Healthcare

Technikai pontszám

By Trading Central

Bizalom

Bullish Evidence

Natera Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2025. okt. 17. 18:13 UTC

Fő piaci mozgatók

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

2025. okt. 17. 17:05 UTC

Fő piaci mozgatók

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

2025. okt. 17. 15:03 UTC

Fő piaci mozgatók

Obook Shares Sink Following Public Debut

2025. okt. 17. 14:41 UTC

Fő piaci mozgatók

Disc Medicine Shares Surge After FDA Grants Priority Voucher for EPP Drug

2025. okt. 17. 23:25 UTC

Felvásárlások, összeolvadások, átvételek

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

2025. okt. 17. 22:15 UTC

Piaci beszéd

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

2025. okt. 17. 21:15 UTC

Piaci beszéd

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

2025. okt. 17. 21:07 UTC

Piaci beszéd

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

2025. okt. 17. 21:07 UTC

Piaci beszéd

Global Equities Roundup: Market Talk

2025. okt. 17. 20:50 UTC

Piaci beszéd

Basic Materials Roundup: Market Talk

2025. okt. 17. 20:34 UTC

Piaci beszéd

Deere Is Reaching the End of Its Downcycle -- Market Talk

2025. okt. 17. 20:27 UTC

Piaci beszéd

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

2025. okt. 17. 19:46 UTC

Piaci beszéd

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025. okt. 17. 19:45 UTC

Piaci beszéd

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

2025. okt. 17. 18:45 UTC

Piaci beszéd

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

2025. okt. 17. 17:51 UTC

Piaci beszéd

Global Forex and Fixed Income Roundup: Market Talk

2025. okt. 17. 17:51 UTC

Piaci beszéd

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

2025. okt. 17. 17:44 UTC

Piaci beszéd

EQT Seen With Long-Term Growth Opportunities -- Market Talk

2025. okt. 17. 17:35 UTC

Piaci beszéd

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

2025. okt. 17. 16:20 UTC

Piaci beszéd
Eredményjelentés

Tech, Media & Telecom Roundup: Market Talk

2025. okt. 17. 16:20 UTC

Piaci beszéd

Basic Materials Roundup: Market Talk

2025. okt. 17. 16:14 UTC

Piaci beszéd

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

2025. okt. 17. 16:04 UTC

Piaci beszéd

Home Improvement Demand Is Starting to Pick Up -- Market Talk

2025. okt. 17. 15:58 UTC

Piaci beszéd

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

2025. okt. 17. 15:56 UTC

Eredményjelentés

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

2025. okt. 17. 15:43 UTC

Piaci beszéd

Global Equities Roundup: Market Talk

2025. okt. 17. 15:43 UTC

Piaci beszéd

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

2025. okt. 17. 14:58 UTC

Piaci beszéd

Small-Business Trepidation in Canada Points to Economic Decline -- Market Talk

2025. okt. 17. 14:41 UTC

Piaci beszéd

Global Forex and Fixed Income Roundup: Market Talk

2025. okt. 17. 14:35 UTC

Piaci beszéd
Eredményjelentés

American Express's Delayed Card Fee Hike Worries Some Investors -- Market Talk

Társak összehasonlítása

Árváltozás

Natera Inc Előrejelzés

Célár

By TipRanks

14.69% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 207.07 USD  14.69%

Magas 268 USD

Alacsony 175 USD

17 Wall Street elemző 12 hónapos célárain alapulva a(z)Natera Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

17 ratings

16

Vétel

1

Tartás

0

Eladás

Technikai pontszám

By Trading Central

153.79 / N/ATámogatás & ellenállás

Rövid táv

Bullish Evidence

Középtáv

Strong Bullish Evidence

Hosszú táv

Bullish Evidence

Hangulat

By Acuity

157 / 371 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag feletti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
help-icon Live chat